IT 901

Drug Profile

IT 901

Alternative Names: IT-901

Latest Information Update: 10 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmuneTarget
  • Class Antineoplastics; Small molecules
  • Mechanism of Action NF kappa B kinase inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Multiple myeloma; Multiple sclerosis

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Chronic lymphocytic leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 10 Aug 2016 IT 901 is available for licensing as of 10 Aug 2016. http://www.immunetarget.com/
  • 10 Aug 2016 Preclinical trials in Chronic lymphocytic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top